Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) – cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom

References

• Barbour T, Johnson S, Cohney S, et al. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012 Jul 1;27(7):2673–2685.
   PubMed Web of Science ®Google Scholar
• Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005 Jul 1;3(7):1432–1436.
   PubMed Web of Science ®Google Scholar
• Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017 May 25;129(21):2836–2846.
   PubMed Web of Science ®Google Scholar
• Patschan D, Witzke O, Dührsen U, et al. Acute myocardial infarction in thrombotic microangiopathies – clinical characteristics, risk factors and outcome. Nephrol Dial Transplant. 2006 Mar 30;21(6):1549–1554.
   PubMed Web of Science ®Google Scholar
• Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 Feb;15(2):312–322.
   PubMed Web of Science ®Google Scholar
• Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008 Sep;142(5):819–826.
   PubMed Web of Science ®Google Scholar
• Sukumar S, Lämmle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. J Clin Med. 2021 Feb 2;10(3):536.
   PubMed Web of Science ®Google Scholar
• Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008 Jul 1;112(1):11–18.
   PubMed Web of Science ®Google Scholar
• Nichols L, Berg A, Rollins-Raval MA, et al. Cardiac injury is a common postmortem finding in thrombotic thrombocytopenic purpura patients: is empiric cardiac monitoring and protection needed? Ther Apher Dial. 2015 Feb 1;19(1):87–92.
   PubMed Web of Science ®Google Scholar
• Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013 Sep 19;122(12):2023–2029.
   PubMed Web of Science ®Google Scholar
• Vesely SK. Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost. 2015 Jun 19;13(S1):S216–S222.
   PubMedGoogle Scholar
• Frawley N, Ng AP, Nicholls K, et al. Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: a single-centre experience. Intern Med J. 2009 Mar 5;39(1):19–24.
   PubMed Web of Science ®Google Scholar
• Hovinga JAK, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010 Feb 25;115(8):1500–1511.
   PubMed Web of Science ®Google Scholar
• Lewis QF, Lanneau MS, Mathias SD, et al. Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion (Paris). 2008 Dec 23;49(1):118–124.
   Web of Science ®Google Scholar
• Han B, Page EE, Stewart LM, et al. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol. 2015 Aug 1;90(8):709–714.
   PubMed Web of Science ®Google Scholar
• Kennedy AS, Lewis QF, Scott JG, et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion (Paris. 2009 Jun 1;49(6):1092–1101.
   PubMed Web of Science ®Google Scholar
• Harrington RL, Hanna ML, Oehrlein EM, et al. Defining patient engagement in research: results of a systematic review and analysis: report of the ISPOR patient-centered special interest group. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2020;23(6):677–688.
   PubMed Web of Science ®Google Scholar
• Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care. 1992 Jun 1;30(6):473–483.
   PubMed Web of Science ®Google Scholar
• Maruish ME. User’s manual for the SF-36v2 Health Survey. 3rd ed. Lincoln (RI): QualityMetric, Inc.; 2011.
   Google Scholar
• Cella D, Riley W, Stone A, et al. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010 Nov 1;63(11):1179–1194.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun 1;67(6):361–370.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993 Nov 1;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Stewart-Brown S, Petersen S, et al. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999 Jan 1;53(1):46–50.
   PubMed Web of Science ®Google Scholar
• Ware JE, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA project. International quality of life assessment. J Clin Epidemiol. 1998 Nov 1;51(11):1167–1170.
   PubMed Web of Science ®Google Scholar
• Oladapo A, Ito D, Hibbard C, et al. Development of a patient-reported outcome (PRO) instrument for patients with acquired thrombotic thrombocytopenic purpura. Value Health. 2018 May;21(S1):S257.
   Google Scholar
• Falter T, Schmitt V, Herold S, et al. Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura. Transfusion (Paris). 2017 May 1;57(5):1152–1162.
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, Oluwole O, Cataland S, et al. Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. Thromb Res. 2017 Mar 1;151:51–56.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Gooch KL, Wong RL, et al. Impact of age, sex, physical function, health-related quality of life, and treatment with Adalimumab on work status and work productivity of patients with Ankylosing Spondylitis. J Rheumatol. 2010 Feb 1;37(2):385–392.
   PubMed Web of Science ®Google Scholar
• Alwan F, Mahdi D, Tayabali S, et al. Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura. Br J Haematol. 2020 Dec;191(5):868–874.
   PubMed Web of Science ®Google Scholar
• Riva S, Mancini I, Maino A, et al. Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura. Haematologica. 2020 Jul 1;105(7):1957–1962.
   PubMed Web of Science ®Google Scholar
• Terrell DR, Tolma EL, Stewart LM, et al. Thrombotic thrombocytopenic purpura patients’ attitudes toward depression management: a qualitative study. Health Sci Rep. 2019 Aug 29;2(11):e136.
   PubMedGoogle Scholar
• Siegert RJ. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005 Apr 1;76(4):469–475.
   PubMed Web of Science ®Google Scholar
• Ayerbe L, Ayis S, Crichton S, et al. The natural history of depression up to 15 years after stroke: the South London Stroke Register. Stroke. 2013 Apr 1;44(4):1105–1110.
   PubMed Web of Science ®Google Scholar
• Weathers F, Litz B, Keane T, et al. The PTSD Checklist for DSM-5 (PCL-5) [Internet]. 2013. Available from: www.ptsd.va.gov.
   Google Scholar